Skip to content

Psychedelic-assisted therapy: all studies

Page 80 of 294: studies 791 to 800 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nature Medicine November 1, 2024 Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al. 4 citations

In the version of the article initially published, some members of the MAPP2 Study Collaborator Group were listed only in the Supplementary Information. Charlotte Harrison, Berra Yazar-Klosinski, Wael Garas, Darrick May, Cole Marta, Susan Walker, Elizabeth Nielson, Gregory Wells, Randall Brown, Revital Amiaz, Yair Wallach, Ray Worthy, Alia Lilienstein and Amy Emerson have now been added to the...

Psychedelic and MDMA-Related Adverse Effects-A Call for Action.

JAMA Health Forum November 1, 2024 Otto Simonsson, Matthew W. Johnson, Peter S. Hendricks 10 citations

This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.

DOI: 10.1001/jamahealthforum.2024.3630 (opens in new tab) Psychedelic therapy Adverse effects Patient safety Preparation & integration

Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention.

Molecular Psychiatry November 1, 2024 H Nur Eken, Crystal Spotts, Benjamin Panny et al. 1 citation

In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to extend the rapid antidepressant effect of a single infusion of ketamine for at least 30 days. In this secondary analysis, we aimed to understand the potential role of implicit self-esteem in the combined antidepressant effect of ketamine and ASAT...

How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety?

AMA journal of ethics November 1, 2024 Zachary J Verne, Jeffrey S Zabinski 1 citation

Psychedelics have long been used by individuals seeking peace and a sense of wellness. This article examines widespread adoption of ketamine as a proxy for psychedelics. For ketamine, there is a need to protect vulnerable persons from exploitation that should be balanced against risks of hypermedicalization. This article suggests strategies for striking such a balance, including by carefully...

DOI: 10.1001/amajethics.2024.868 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Ketamine clinics Medical safety protocols Mental health treatment +1

Psychoanalysis and psychedelics: The censored story in Argentina.

International Journal of Drug Policy November 1, 2024 Rodolfo Olivieri, Luís Fernando Tófoli 1 citation

This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, it examines the intersection of psychedelics and psychoanalysis, drawing from historical texts and writings by local psychoanalysts to develop a comprehensive understanding of the distinctive clinical practices and therapeutic approaches in the...

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada

PLoS One October 24, 2024 Kyurim Kim, Abban Yusuf, Abhimanyu Sud et al. 1 citation

Psychedelics, including ketamine, 3,4-Methyl enedioxy methamphetamine (MDMA), and psilocybin, have gained attention for their potential therapeutic role in mental health treatment. While recreational use is prohibited in Canada, medicinal exemptions can be granted. There are several psychedelic clinics in Ontario, Canada, promoting the use of psychedelics for a variety of medical indications....

DOI: 10.1371/journal.pone.0309911 (opens in new tab) Psychedelic therapy Mental health treatment Clinical research Medical ethics +1

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.

PsyArXiv October 18, 2024 Jake Hooper, Emily L Gyongyosi, Kent E. Hutchison et al. preprint

Objective: The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains unexplored. This study investigates the role of psychedelic-induced aesthetic experiences in predicting positive psychological outcomes. Methods: Using a cross-sectional naturalistic survey, participants who had recently used classic...

DOI: 10.31234/osf.io/u9yeg (opens in new tab) Psychedelic therapy Mental health research Therapeutic outcomes Psychedelic experiences +1

Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science

Translational Behavioral Medicine October 17, 2024 Danielle R Adams, Heidi L Allen, Ginger E. Nicol et al. 7 citations

Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use...

The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies

Research Square October 15, 2024 Alexandra R. Gordon, Brennan M. Carrithers, Broc A. Pagni et al. 3 citations preprint

Abstract Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about safety or potential therapeutic...